Research Library / Blends / Wolverine
Blends researchWolverine
BPC-157 + TB-500 community blend
A community name for combining BPC-157 and TB-500. The listed community schedules describe individual components; they do not establish a single total-blend amount or frequency. An illustrative 20 mg total-blend vial at an assumed 2 mL final volume yields 10 mg/mL; diluent compatibility remains product-specific. For research and education only, not personal medical guidance.
Quick Reference
- Example vial
- 20mg
- Assumed final volume
- 2mL · not an amount to add
- Concentration
- 10mg/mL · conditional arithmetic
- One U-100 marking
- 100mcg in 0.01 mL
Hypothetical vial math does not reproduce a study formulation or verify a diluent, sterility or storage period.
Research schedules
No established clinical dose, route or frequency
Human evidence is absent, limited or not confirmatoryClinicalTrials.gov| Context / phase | Amount | Schedule total | Frequency | Timing | Route | Evidence |
|---|---|---|---|---|---|---|
| BPC-157 component schedule | 250 mcg | 500 mcg/day | Twice daily | Morning and evening | Subcutaneous | Community-reported |
| TB-500 component schedule | 2–2.5 mg | 4–5 mg/week | Twice weekly | Evenly spaced | Subcutaneous | Community-reported |
Repeated community reports do not establish identity, safety, effectiveness or an appropriate exposure. Component schedules do not validate a same-vial blend.
Vial calculator
Linked to Quick Reference and compatible supply calculations.
Read the needle-side edge of the black stopper. Liquid tint is illustrative.
Scale illustration · one U-100 marking = 0.01 mL.
Arithmetic yield at this example amount
40 example portions per vial
40 full amounts; 0 mg remaining. Yield is not a storage or reuse period.
See the calculation
Concentration = vial content ÷ final volume. Volume = example amount ÷ concentration. U-100 markings = mL × 100.
Original example & formulation context
500 mcg total blend (250/250 mcg) · 10 mg/mL · 0.05 mL · 5 units
Assumes a labeled 1:1 vial containing 10 mg BPC-157 + 10 mg TB-500. At 10 mg total blend/mL, 250 mcg of each component equals 0.05 mL (5 U-100 units). This fixed ratio does not reproduce separately adjusted component schedules. The fixed-ratio BPC-157/TB-500 blend is a finished mixture; separate component findings and solvent specifications do not establish its compatibility. The calculation assumes the stated final solution volume, which may differ from liquid added. It does not verify dissolution, solvent compatibility, sterility, chemical stability or storage. See the source-linked preparation notes below.
Supplies & vial yield
20 mg (hypothetical) · 2 mL assumed final solution volume; diluent product-specific · BPC-157 component schedule
Vial counts and final solution totals below use the selected 20 mg example at 2 mL. The original schedule totals stay unchanged.
Schedule phases used for planning
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Selected planning schedule | 250 mcg | Twice daily | 3.5 mg/week |
Peptide vials
| Horizon | Total | Vials* |
|---|---|---|
| 4 weeks | 14 mg | 1 × 20 mg |
| 8 weeks | 28 mg | 2 × 20 mg |
| 12 weeks | 42 mg | 3 × 20 mg |
Liquid planning
| Horizon | Final volume* | Diluent supplies |
|---|---|---|
| 4 weeks | 2 mL | Not established |
| 8 weeks | 4 mL | Not established |
| 12 weeks | 6 mL | Not established |
Administration count
| Horizon | Administrations |
|---|---|
| 4 weeks | 56 |
| 8 weeks | 112 |
| 12 weeks | 168 |
Original schedule counts. Check the calculated volume against syringe capacity; no split-dose technique is assigned.
Original vial-life context
4 weeks: 80 administrations
8 weeks: 80 administrations
12 weeks: 80 administrations
Applies to the original planning basis above; not a product stability period.
Ranges reflect the low and high ends of the selected displayed schedule (community-reported). Vials are rounded up; one new U-100 syringe is counted per subcutaneous administration. Liquid totals are conditional final solution volumes, not verified quantities to add. Diluent bottle counts are withheld pending product-specific preparation instructions. Arithmetic does not establish storage or reuse periods.
*Conditional mass and final-volume arithmetic. No stability, sterility, safe reuse period or verified diluent quantity is established. Cleansing materials, sterile supplies, labels and sharps disposal follow the actual research procedure.
Protocol overview & research context
- Identity
- Wolverine · BPC-157 + TB-500 community blend
- Evidence / status
- Unestablished blend. No FDA-approved combination product
- Clinical route, frequency & duration
Evidence landscape: No established clinical dose, route or frequency
- Community purpose
- Soft-tissue, tendon or ligament, GI, and injury-recovery discussions combining the reported purposes of BPC-157 and TB-500.
Community-reported component loading phase
Initial phase: First 4–6 weeks
Pattern: TB-500 component: 2–2.5 mg twice weekly; BPC-157 component: 250 mcg twice daily
Transition: Then the TB-500 component is commonly reduced to 2–2.5 mg once weekly
This is component-level context. A finished blend cannot be converted to syringe volume unless the exact amount of each component and final concentration are known.
Reconstitution & formulation
The fixed-ratio BPC-157/TB-500 blend is a finished mixture; separate component findings and solvent specifications do not establish its compatibility.
Other vehicles and approaches discussed
No universal alternative diluent or blend-specific chemical/microbial stability period was established. The 1:1 card remains conditional concentration arithmetic.
- Evidence context
- Product / laboratory / report distinctions apply
- Cloudiness / gel signal
- Finished-blend evidence limited
- Product details to verify
- Verify the exact product, sequence/salt form, buffer and excipients, concentration, route, container and product-specific storage instructions.
Sources apply to the named product, laboratory method or report only. Laboratory solvents and community repetition do not establish an injectable preparation, sterility, chemical stability or a beyond-use period. No solvent-mixing or salvage recipe is provided.
Preparation references reviewed October 20, 2026.
Preparation documentation checklist
- Confirm identity, nominal content, salt form, buffer and excipients.
- Verify the actual product's diluent, amount to add and intended method.
- Calculate concentration from final solution volume, and cross-check units.
- Record lot, concentration, diluent, preparation date, storage and discard instructions.
This checklist does not replace a validated preparation procedure.
Storage, clarity & stability
- Unopened product
- Follow its documented temperature, light protection, shipping and expiration requirements.
- Prepared material
- Chemical stability and microbial safety are formulation-specific. A diluent bottle's discard period does not establish the compound's storage period.
- Visible-change context
- Finished-blend evidence limited
Unexpected cloudiness, particles or gel
For a product intended to form a clear solution, do not use or attempt to salvage unexpected persistent clouding, strings, precipitate, thickening or gel. Labeled suspensions, including some triptorelin depots, have their own expected appearance and instructions.
Why vial yield does not establish shelf life
Arithmetic portions assume the material remains usable. Chemical degradation, contamination, handling losses and required discard limits may reduce practical yield. Freezing, warming, acidifying or further diluting cannot be assumed to restore quality.
No universal refrigerated, room-temperature or 90-day beyond-use period is assigned by the calculator.
How it works
Combines proposed cytoprotective and actin-related tissue signaling
A community name for combining BPC-157 and TB-500. Evidence for either component does not establish the safety or effectiveness of the combination.
Community-reported purpose
Soft-tissue, tendon or ligament, GI, and injury-recovery discussions combining the reported purposes of BPC-157 and TB-500.
Reported purposes and marketing use-cases are not an approved indication or proof of efficacy.
Clinical findings & study landscape
Evidence landscape
Protocol: No established clinical dose, route or frequency
Population: Human evidence is absent, limited or not confirmatory
Read the cited evidenceFindings apply to the tested product, population and methods. A registry listing, mechanistic study or evidence-landscape link is not itself proof of efficacy or validation of an online vial.
Safety, evidence limits & regulatory status
Compound-specific safety context
No controlled human study has established a fixed ratio, interaction profile, or long-term safety for this blend.
Development and regulatory status
No FDA-approved combination product
Approval of a named product does not extend to every vial, formulation, route, blend or indication carrying a related name.
What this guide cannot establish
The library does not authenticate a product or determine a personal starting dose, missed-dose rule, restart regimen, interaction plan or combination protocol. Study schedules, community reports and vial calculations retain separate evidence labels.
Frequently asked questions
What is Wolverine?
A community name for combining BPC-157 and TB-500. Evidence for either component does not establish the safety or effectiveness of the combination.
Combines proposed cytoprotective and actin-related tissue signaling
Does vial strength mean the amount per administration?
No. A vial's label states nominal contents. The amount used in a study belongs to its assigned product and protocol. Changing vial strength changes concentration and yield, not the study's assigned amount.
Why does changing final volume change the U-100 value?
A larger final volume reduces concentration for the same mass. U-100 markings are volume measurements: one marking equals 0.01 mL. They are not biological international units of a peptide.
What happens when a calculation exceeds one syringe or vial?
Available mass and syringe capacity are separate limits. The calculator flags a result above 1 mL; it does not provide a splitting or combining technique.
Is there a loading phase or standard cycle?
Community-reported component loading phase: First 4–6 weeks. This is component-level context. A finished blend cannot be converted to syringe volume unless the exact amount of each component and final concentration are known.
Cycle length is not established as a universal protocol.
Which diluent and storage period should this material use?
The fixed-ratio BPC-157/TB-500 blend is a finished mixture; separate component findings and solvent specifications do not establish its compatibility.
Calculation examples do not establish solvent compatibility, sterility or shelf life.
Where do I track or calculate a multi-phase schedule?
The Free Planner supports saved research examples and multi-phase planning. This guide's calculator is local to the page and does not save a protocol automatically.
Open Free PlannerReferences & evidence trail
- Clinical / regulatory / evidence landscapeClinicalTrials.gov: Evidence landscape
- Laboratory supplier or secondary reference — product-specificWolverine supplier product
- Laboratory supplier or secondary reference — product-specificCayman TB-500 acetate insert
Clinical sources remain attached to their studies; laboratory and community formulation sources retain their own limits. Preparation review dates do not imply that every clinical study was newly reviewed today.
Independent educational research reference. Not medical advice or an individualized dosing recommendation.